Joseph D. Allen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Joseph D. Allen has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
Alexandra Sokolova
Division of Hematology/Medical Oncology, School of Medicine, Oregon Health & Sciences University, Portland, OR
1 shared publication- Ali Raza Khaki
Division of Oncology, Department of Medicine, Stanford University, Stanford, CA
1 shared publication Burcak Yilmaz
Division of Hematology/Medical Oncology, School of Medicine, Oregon Health & Sciences University, Portland, OR
1 shared publicationC. Jackson White
Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, USA
1 shared publication- Cameron Chalker
Division of Hematology and Medical Oncology Oregon Health & Science University (OHSU), Knight Cancer Institute Portland Oregon USA
1 shared publication Charles Xu
Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, USA
1 shared publication
Latest Publications
- Open Access
- 30 April 2026
- Published by Elsevier in Clinical Genitourinary Cancer
- Vol. 24 (5) , 102569
Baseline Hematological Parameters and Outcomes in Patients With Prostate Cancer Treated With Lu-177 PSMA Radioligand Therapy (RLT): A Multicenter Real-World Analysis
- 30 April 2026
- Published by Elsevier in Clinical Genitourinary Cancer
- Vol. 24 (5) , 102569
Open AccessBaseline Hematological Parameters and Outcomes in Patients With Prostate Cancer Treated With Lu-177 PSMA Radioligand Therapy (RLT): A Multicenter Real-World Analysis
- Open Access
- 3 April 2023
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1-22
Workflow enabling deepscale immunopeptidome, proteome, ubiquitylome, phosphoproteome, and acetylome analyses of sample-limited tissues
Serial multi-omic analysis of proteome, phosphoproteome, and acetylome provides insights into changes in protein expression, cell signaling, cross-talk and epigenetic pathways involved in disease pathology and treatment. However, ubiquitylome and HLA peptidome data collection used to understand protein degradation and antigen presentation have not together been serialized, and instead require separate samples for parallel processing using distinct protocols. Here we present MONTE, a highly sensitive multi-omic native tissue enrichment workflow, that enables serial, deep-scale analysis of HLA-I and HLA-II immunopeptidome, ubiquitylome, proteome, phosphoproteome, and acetylome from the same tissue sample. We demonstrate that the depth of coverage and quantitative precision of each ‘ome is not compromised by serialization, and the addition of HLA immunopeptidomics enables the identification of peptides derived from cancer/testis antigens and patient specific neoantigens. We evaluate the technical feasibility of the MONTE workflow using a small cohort of patient lung adenocarcinoma tumors.
- 3 April 2023
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1-22
Open AccessWorkflow enabling deepscale immunopeptidome, proteome, ubiquitylome, phosphoproteome, and acetylome analyses of sample-limited tissues
Serial multi-omic analysis of proteome, phosphoproteome, and acetylome provides insights into changes in protein expression, cell signaling, cross-talk and epigenetic pathways involved in disease pathology and treatment. However, ubiquitylome and HLA peptidome data collection used to understand protein degradation and antigen presentation have not together been serialized, and instead require separate samples for parallel processing using distinct protocols. Here we present MONTE, a highly sensitive multi-omic native tissue enrichment workflow, that enables serial, deep-scale analysis of HLA-I and HLA-II immunopeptidome, ubiquitylome, proteome, phosphoproteome, and acetylome from the same tissue sample. We demonstrate that the depth of coverage and quantitative precision of each ‘ome is not compromised by serialization, and the addition of HLA immunopeptidomics enables the identification of peptides derived from cancer/testis antigens and patient specific neoantigens. We evaluate the technical feasibility of the MONTE workflow using a small cohort of patient lung adenocarcinoma tumors.